In order to investigate the efficacy of a combination of JBB as topical and HTGMB as internal treatment method, changes in various immune related factors and histological changes in NC/Nga induced animal model was studied. Combined treatment of topical JBB and internal HTGMB significantly reduced the atopic dermatitis clinical index, the number of immune cells such as CD19+, CCR3+, B220+/IgE+, and Gr-1+/CD11b+ in DLN and dorsal skin, compared to the control group. Otherwise increased CD3+, CD4+/CD25+, CD8+ and CD4+ cells in the DLN. And also combined treatment of topical JBB and internal HTGMB suppressed the lymphocytes and mast cells from infiltrating into the skin tissues when stained with H&E and toluidine blue. Based on the results above, it is strongly suggested that the combined treatment of topical JBB and internal HTGMB significantly induced anti-allergic activities through immune modulation. The findings can be applied to developing a more sustainable treatment for atopic dermatitis and be helpful in practicing combined treatments in clinical treatments in the future.